Publication date: Jul 10, 2025
One reason for this is that many potentially helpful drugs simply cant reach the areas of the brain that need them. How Nanocarriers Overcome a Major Hurdle in Parkinsons TreatmentDelivering medications to the brain is one of the most significant challenges in modern medicine. If medications are delivered broadly throughout the brain, they can lead to unwanted side effects or fail to work effectively. The brain is an intricate organ, and diseases often affect very specific regions. We demonstrated, for the first time, that nanocarriers can successfully deliver an IRAK4 inhibitor to the hypothalamus of mice with cancer cachexia. The results were dramatic. This could help slow or even halt disease progression something no current therapy can do reliably. In experiments on mice, the nanocarriers were used to deliver a drug known as an IRAK4 inhibitor.
| Concepts | Keywords |
|---|---|
| April | Bbb |
| Neuroscience | Brain |
| Oregon | Current |
| Sclerosis | Diseases |
| Drugs | |
| Hypothalamus | |
| Inflammation | |
| Major | |
| Medications | |
| Nanocarriers | |
| Neurological | |
| Parkinsons | |
| Pd | |
| Specific | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Metabolism |
| disease | MESH | inflammation |
| disease | MESH | cancer |
| disease | MESH | causes |
| disease | MESH | weight loss |
| pathway | REACTOME | Release |
| drug | DRUGBANK | Glutathione |
| disease | MESH | neurological disorder |
| drug | DRUGBANK | Dopamine |
| drug | DRUGBANK | Levodopa |
| disease | MESH | disease progression |
| pathway | REACTOME | Immune System |
| disease | MESH | multiple sclerosis |
| disease | MESH | epilepsy |
| disease | MESH | psychiatric disorders |
| disease | MESH | depression |
| disease | MESH | schizophrenia |
| disease | MESH | brain inflammation |
| disease | MESH | brain disorders |